Qiagen

Global Infectious Disease Rapid Diagnostic Testing Market (2020 to 2025) - Focus on Product, Disease, Technology, Application, End User, Region/Country Data, and Competitive Landscape - ResearchAndMarkets.com

Retrieved on: 
Monday, June 15, 2020
Infectious diseases, Biotechnology, Health, Medicine, Health, Medical terminology, Epidemiology, Infection, Medical diagnosis, Infectious disease, Medical tests, Qiagen, Association of Public Health Laboratories

The "Global Infectious Disease Rapid Diagnostic Testing Market: Focus on Product, Disease, Technology, Application, End User, Region/Country Data, and Competitive Landscape - Analysis and Forecast, 2020-2025" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Infectious Disease Rapid Diagnostic Testing Market: Focus on Product, Disease, Technology, Application, End User, Region/Country Data, and Competitive Landscape - Analysis and Forecast, 2020-2025" report has been added to ResearchAndMarkets.com's offering.
  • Infectious disease rapid diagnostic testing has emerged as one of the most promising techniques in the field of diagnostics.
  • Infectious disease rapid diagnostic testing is primarily adopted for the diagnosis of various infectious diseases in a restricted clinical environment.
  • What was the market value of the leading segments of the global infectious disease rapid diagnostics testing market in 2019?

Global Molecular Diagnostics Market - Technologies, Products, Applications and End-Use Sectors to 2022 - ResearchAndMarkets.com

Retrieved on: 
Monday, June 15, 2020
Medical devices, Health, Biotechnology, Molecular diagnostics, Life sciences, Biology, Health, Qiagen, EKF Diagnostics

The "Global Molecular Diagnostics Market - Technologies, Products, Applications and End-Use Sectors" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Molecular Diagnostics Market - Technologies, Products, Applications and End-Use Sectors" report has been added to ResearchAndMarkets.com's offering.
  • Amid the COVID-19 outbreak, the global market for Molecular Diagnostics has created mixed opportunities for manufacturers all over the world.
  • The Global Molecular Diagnostics market has generated a revenue of US$10.85 billion in 2019 and is estimated to be just over US$15 billion in 2020.
  • This most comprehensive report on Molecular Diagnostics, analyzes the global market with respect to technologies, product types, applications and end-use sectors
    Molecular Diagnostics' market size is estimated in this report by product types, technologies, applications and end-use sectors across all major countries
    Key business trends focusing on product innovations/developments, M&As, JVs and other recent industry developments

2020 Coronavirus Diagnostics Market Analysis by Type, Time Duration, Application, End-User and Geography - ResearchAndMarkets.com

Retrieved on: 
Friday, June 12, 2020
Infectious diseases, Biotechnology, Health, Companies, Industries, Life sciences, Medical software, Qiagen, Ortho Clinical Diagnostics, PerkinElmer, Coronavirus, BioMérieux, Becton Dickinson, Beckman Coulter, Bio-Rad Laboratories

The "Coronavirus Diagnostics - Global Market Outlook (2018-2027)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Coronavirus Diagnostics - Global Market Outlook (2018-2027)" report has been added to ResearchAndMarkets.com's offering.
  • The Global Coronavirus Diagnostics market accounted for $4.64 billion in 2018 and is expected to reach $8.82 billion by 2027 growing at a CAGR of 7.4% during the forecast period.
  • Some of the key players profiled in the Coronavirus Diagnostics Market include Abbott, Beckman Coulter, Becton, Dickinson and Company, bioMerieux, Bio-Rad Laboratories, GSK Biologicals, Hologic, Lonza, Ortho-Clinical Diagnostics, PerkinElmer, Qiagen and Roche Diagnostics.
  • Covers Market data for the years 2017, 2018, 2019, 2023 and 2027
    Company profiling with detailed strategies, financials, and recent developments

QIAGEN Builds on Leading Position in Precision Medicine With Novel Solutions in Oncology

Retrieved on: 
Thursday, May 28, 2020
Biotechnology, Pharmaceutical, Health, Oncology, Medical software, Qiagen, Health, Cancer, Systems biology, American Society of Clinical Oncology, Articles, QIA, Precision medicine, Cancer research, Branches of biology

QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of novel solutions enabling faster, better analysis of genomic variations in cancer accelerating multiple applications of Precision Medicine.

Key Points: 
  • QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of novel solutions enabling faster, better analysis of genomic variations in cancer accelerating multiple applications of Precision Medicine.
  • QIAGEN is showcasing its broad portfolio of Sample to Insight solutions for cancer in connection with the 2020 American Society of Clinical Oncology (ASCO) Annual Meeting, being held virtually from May 29-31.
  • While we serve the worlds needs for testing tools in the COVID-19 pandemic, QIAGEN also continues to deliver cutting-edge molecular solutions for cancer research and improving patient outcomes.
  • They create true Sample to Insight solutions for a variety of oncology research applications.

Coronavirus Test Kits Market Segmented by Government and Non-Government End-Users with Regional Analysis

Retrieved on: 
Wednesday, May 27, 2020
Companies, Coronaviridae, Medical software, Qiagen, Market research, Coronavirus, Danaher Corporation, Thermo Fisher Scientific

The coronavirus testing kits market covers the following areas:

Key Points: 
  • The coronavirus testing kits market covers the following areas:
    The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading coronavirus testing kits market vendors that include Abbott Laboratories, BGI Genomics Co. Ltd., Danaher Corp., F. Hoffmann-La Roche Ltd., Hologic Inc., Laboratory Corp. of America Holdings, QIAGEN GmbH, Seegene Inc., SolGent Co. Ltd., and Thermo Fisher Scientific Inc. Also, the coronavirus testing kits market analysis report includes information on upcoming trends and challenges that will influence market growth.
  • The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry.
  • The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
  • This market research report provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast an accurate market growth.

Global Bioinformatics Industry Analysis, 2014-2024 Featuring Profiles of Leading Players Including Illumina, Life Technologies, Qiagen, Agilent Technologies, and PerkinElmer

Retrieved on: 
Tuesday, May 19, 2020
Medical software, Qiagen, Bioinformatics, Illumina, Inc., Biotechnology, Branches of biology, Biology

The Global Bioinformatics Market is anticipated to grow at a CAGR of close to 18% during the forecast period, reaching a market value of approximately $14 billion by 2024.

Key Points: 
  • The Global Bioinformatics Market is anticipated to grow at a CAGR of close to 18% during the forecast period, reaching a market value of approximately $14 billion by 2024.
  • The factors responsible for the growth of the bioinformatics market includes rise in nucleic acid and protein sequencing and increasing initiatives from the government and private organizations.
  • The Global Bioinformatics Market can be segmented based on product & services, applications, sectors and regional analysis.
  • The major players operating in the Global Bioinformatics Market include Illumina Inc. Life Technologies (Thermo Fischer Scientific), Qiagen NV, Agilent Technologies, PerkinElmer, Accelrys Inc., Geneva Bioinformatics SA, Ontoforce, Data4Cure and Life Map Sciences (Biotime).

Global Molecular Diagnostics Markets, Forecast to 2029: Technologies, Applications, Regulations and Companies - ResearchAndMarkets.com

Retrieved on: 
Tuesday, May 19, 2020
Health, Biotechnology, Medical genetics, Medical tests, Companies, Life sciences, Branches of biology, Biotechnology, Molecular diagnostics, Agilent Technologies, Microarrays, Qiagen, CombiMatrix

The "Molecular Diagnostics - Technologies, Markets and Companies" report from Jain PharmaBiotech has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Molecular Diagnostics - Technologies, Markets and Companies" report from Jain PharmaBiotech has been added to ResearchAndMarkets.com's offering.
  • The most comprehensive and up-to-date one-stop source of information on technical and commercial aspects of molecular diagnostics.
  • The number of companies involved in molecular diagnostics has increased remarkably during the past few years.
  • A new edition in 1997 "Molecular Diagnostics I" as well as the next edition, "Molecular Diagnostics II" in 1999, were published by Decision Resources Inc, USA.

QIAGEN Announces Publication of Reasoned Position Statement for Proposed Acquisition by Thermo Fisher and Date for Annual General Meeting

Retrieved on: 
Monday, May 18, 2020
Health, Clinical trials, Research, Pharmaceutical, Science, Biotechnology, Medical software, Qiagen, Companies, Corporate finance, Tender offer, Thermo Fisher Scientific, Organizations, Articles

The Offer Document relates to the recommended offer by Thermo Fisher to fully acquire all issued shares in QIAGEN as announced on March 3, 2020.

Key Points: 
  • The Offer Document relates to the recommended offer by Thermo Fisher to fully acquire all issued shares in QIAGEN as announced on March 3, 2020.
  • QIAGEN has published the Joint Reasoned Position Statement of the Managing Board and the Supervisory Board in accordance with Section 27 para.
  • Additionally, QIAGEN announced that the Annual General Meeting of Shareholders (AGM) is planned to be held on June 30, 2020, at 15:00 CEST.
  • In addition, Thermo Fishers tender offer statement and other documents it files with the SEC are available at https://ir.thermofisher.com/investors .

Analysis on Impact of COVID-19 - Helicobacter Pylori Diagnostics Market 2020-2024 | Resistance of H. Pylori to Antibiotics to Boost Growth | Technavio

Retrieved on: 
Thursday, May 14, 2020
Biotechnology, General Health, Infectious diseases, Health, Pharmaceutical, Medical specialties, Medicine, Bacteria, Helicobacter pylori, Medical software, Qiagen, Helicobacter, Thermo Fisher Scientific, Abbott Laboratories

Our helicobacter pylori diagnostics market report covers the following areas:

Key Points: 
  • Our helicobacter pylori diagnostics market report covers the following areas:
    This study identifies growing shift toward direct-to-consumer testing as one of the prime reasons driving the helicobacter pylori diagnostics market growth during the next few years.
  • Helicobacter Pylori Diagnostics Market 2020-2024: Vendor Analysis
    We provide a detailed analysis of vendors operating in the helicobacter pylori diagnostics market, including some of the vendors such as Abbott Laboratories, Becton, Dickinson and Co., bioMrieux SA, Bio-Rad Laboratories Inc., Cardinal Health Inc., F. Hoffmann-La Roche Ltd., Omega Diagnostics Group Plc, QIAGEN N.V., Quest Diagnostics Inc., and Thermo Fisher Scientific Inc.
  • Backed with competitive intelligence and benchmarking, our research reports on the helicobacter pylori diagnostics market are designed to provide entry support, customer profile and M&As as well as go-to-market strategy support.
  • Helicobacter Pylori Diagnostics Market 2020-2024: Key Highlights

QIAGEN Reports Full Results for First Quarter of 2020

Retrieved on: 
Wednesday, May 6, 2020
Cardiology, Software, Biotechnology, Pharmaceutical, Health, Data management, Technology, Genetics, Medical software, Qiagen, Corporate finance, Financial ratios, Fundamental analysis, Companies, Economy, Earnings per share, QIA, Finance, BlackBerry Limited

QIAGEN N.V. (NYSE:QGEN; Frankfurt Prime Standard:QIA) announced full results of operations for the first quarter of 2020, with net sales and adjusted earnings per share (EPS) in line with the preliminary results announced on April 9, 2020.

Key Points: 
  • QIAGEN N.V. (NYSE:QGEN; Frankfurt Prime Standard:QIA) announced full results of operations for the first quarter of 2020, with net sales and adjusted earnings per share (EPS) in line with the preliminary results announced on April 9, 2020.
  • Net sales grew 7% (+9% at constant exchange rates, or CER) and adjusted earnings per share were $0.34 CER.
  • QIAGEN employees around the world are fully mobilized to address the significant demand for testing solutions needed in the global response to the coronavirus pandemic.
  • Based on trends to date, we expect ongoing strong growth for the second quarter of 2020 in both sales and adjusted earnings per share.